Metabolic associated fatty liver disease induced cirrhosis: epidemiology, risk factors, and new strategies for precise prevention and control
10.3760/cma.j.cn501113-20250401-00117
- VernacularTitle:代谢相关脂肪性肝硬化：流行病学、风险因素与精准防控新策略
- Author:
Xue BAI
1
;
Qianqian CHEN
;
Jie LI
Author Information
1. 南京大学医学院附属鼓楼医院感染性疾病科，南京 210008
- Publication Type:Journal Article
- Keywords:
Metabolic associated fatty liver disease;
Cirrhosis;
Diagnosis;
Therapeutic
- From:
Chinese Journal of Hepatology
2025;33(8):728-733
- CountryChina
- Language:Chinese
-
Abstract:
Cirrhosis caused by metabolic associated fatty liver disease (MAFLD) has become a major global health challenge. Genetics, metabolic disorders, viruses, and other factors jointly drive the progression of this disease. The development of high-precision, non-invasive models for these diseases within the context of artificial intelligence is a novel direction for future diagnosis. Therapies that improve metabolism and antifibrosis should be strongly emphasized and urgently implemented to establish a standardized and unified endpoint evaluation system for anti-cirrhosis drug trials and therefore accelerate new drug development. This article systematically explores the epidemiological characteristics, risk factors, and the latest diagnosis and treatment strategies, with the aim to provide a reference basis for clinical practice.
